Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-NaiVe Psoriatic Arthritis

被引：0
|
作者：
Strand, Vibeke [1 ]
Husni, M. Elaine [2 ]
Singh, Rakesh [3 ]
Betts, Keith [4 ]
Song, Yan [5 ]
Griffith, Jenny [3 ]
Ganguli, Arijit [3 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Los Angeles, CA USA
[5] Anal Grp Inc, Boston, MA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1561
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy of ustekinumab in biologic-naive patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
    McInnes, Iain B.
    Chakravarty, Soumya D.
    Apaolaza, Isabel
    Kafka, Shelly
    Hsia, Elizabeth C.
    You, Yin
    Kavanaugh, Arthur
    RMD OPEN, 2019, 5 (02):
  • [42] Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
    Lu, Chenyang
    Wallace, Beth I.
    Fu, Wenyi
    Liu, Yi
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [43] Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naive or tumor necrosis factor inhibitor inadequate responders
    Wu, Dan
    Hou, Si-Yuan
    Zhao, Shuai
    Hou, Lin-Xin
    Jiao, Ting
    Xu, Nan-Nan
    Zhang, Ning
    CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2747 - 2756
  • [44] Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naive Patients with Rheumatoid Arthritis
    Aletaha, Daniel
    Sawant, Ruta
    Zueger, Patrick
    Cook, Erin
    Mu, Fan
    Garg, Vishvas
    Betts, Keith A.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [45] Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis
    Xie, Ouyang
    Wu, Meiyu
    Li, Andong
    Meng, Kehui
    Xiang, Heng
    Tan, Chongqing
    Peng, Liubao
    Ge, Yan
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [46] Efficacy and safety of ixekizumab at week 52 in biologic-naive patients with active psoriatic arthritis (SPIRIT-P1)
    Lespessailles, E.
    Kirkham, B.
    Nebro, A.
    Alonso, R.
    Strehblow, C.
    Inciarte, J.
    Porsdal, V.
    Garcia, M.
    Kurzawa, M.
    Sapin, C.
    Geusens, P.
    Goupille, P.
    Tahir, H.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 44 - 45
  • [47] Comparative effectiveness of secukinumab and etanercept in biologic-naive patients with psoriatic arthritis assessed by matching-adjusted indirect comparison
    Mease, Philip
    Choy, Ernest
    Nash, Peter
    Kalyvas, Chrysostomos
    Hunger, Matthias
    Pricop, Luminita
    Gandhi, Kunal K.
    Jugl, Steffen M.
    Thom, Howard
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2019, 6 (03) : 113 - +
  • [48] Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis
    Song, Gwan Gyu
    Lee, Young Ho
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (06) : 433 - 441
  • [49] Direct Comparison of Four Biologics in Biologic-naive Rheumatoid Arthritis Patients
    Yonemoto, Yukio
    Takeuchi, Kimihiko
    Okamura, Koichi
    Matsushita, Masatoshi
    Kobayashi, Tsutomu
    Aramaki, Tetsuo
    Kaneko, Tetsuya
    Takagishi, Kenji
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S483 - S483
  • [50] Patterns of Care for Biologic-Dosing Outliers and Nonoutliers in Biologic-Naive Patients with Rheumatoid Arthritis
    Delete, Thomas
    Meyer, Roxanne
    Jenkins, Daniel
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (08): : 798 - 808
12345